Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2018-07-01 Capital/Financing Update
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Appendix 3B LTIP 12 pages 785.4KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new ordinary shares, including the number of shares issued, issue price, terms of the securities, and compliance with ASX listing rules. It includes sections on placement capacity calculations under ASX rules 7.1 and 7.1A, which relate to the company's ability to issue new shares without shareholder approval. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding a new share issue and application for quotation of additional securities. It does not contain financial statements, management discussion, or audit information, nor is it a report or presentation. It is a regulatory announcement specifically about capital raising and share issuance. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length is substantial (15,000 characters), indicating it is the announcement itself, not just a brief notice or report publication announcement.
2018-07-01 English
Change of Director's Interest Notice 2 pages 459.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the transaction (on-market trade), and dates. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3619 characters, consistent with a notice rather than a full report. Therefore, the correct classification is DIRS with high confidence.
2018-06-27 English
Change of Director's Interest Notice - Amended 2 pages 459.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the transaction, and dates. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing'. The document length is 3604 characters, which is consistent with a detailed notice but not a full report. Therefore, the correct classification is DIRS (Director's Dealing).
2018-06-26 English
Change of Director's Interest Notice 2 pages 459.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the transaction (on-market trade), and dates. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing'. The document length is 3618 characters, which is typical for such notices. Therefore, the correct classification is DIRS (Director's Dealing).
2018-06-25 English
Chairman's Address to Shareholders 4 pages 389.5KB
AGM Information Classification · 95% confidence The document is a detailed transcript of the Chairman's address at the Annual General Meeting (AGM) of Cyclopharm Limited held on 29 May 2018. It includes an introduction, overview of the company's performance in the 2017 financial year, strategic priorities, financial results, operational updates, and future outlook. The text explicitly mentions the AGM, the presence of the quorum, introduction of directors and management, and references to the Notice of Annual General Meeting, Financial Statements, Independent Auditor's Report, and other meeting materials. The content is consistent with materials shared during an AGM, including speeches and presentations to shareholders. The document length is 9287 characters, which is substantial and contains the actual meeting content rather than just an announcement or a brief summary. Therefore, this document fits the category of AGM Information (AGM-R).
2018-05-28 English
Managing Director's Address to Shareholders 9 pages 183.3KB
AGM Information Classification · 95% confidence The document is a detailed presentation given at the 2018 Annual General Meeting (AGM) of Cyclopharm Ltd. It includes slides with company overview, financial results for FY2017, strategic priorities, product information, and updates on clinical trials and market opportunities. The presence of slide references, the Managing Director's address, and the focus on updating shareholders about the company's performance and future plans strongly indicate this is AGM presentation material. The document length (15,000 characters) and content depth confirm it is the presentation itself, not just an announcement of the AGM or a brief summary. Therefore, the document fits the category of AGM Information (AGM-R).
2018-05-28 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.